Redacted FDA Listening session

On June 10, 2021, a group of patients and families affected by Arginase 1 Deficiency (ARG1-D) participated in a one-hour virtual listening session with officials from the Food and Drug Administration (FDA). The session enabled those with ARG1-D and their caregivers to  share their experiences, perspectives, needs, goals with officials from across the agency.
During the session the patients and caregivers shared:
  • Difficulties obtaining a correct diagnosis
  • Symptoms and experiences related to living with ARG1-D
  • The impact or the condition on daily functioning and quality of life
  • Experiences and challenges with existing treatments and the current state of disease management
  • The need for disease awareness, improved care guidelines, and better treatment options

FDA Family-Led Listening Session Report

On June 10, 2021, a group of patients and families affected by Arginase 1 Deficiency (ARG1-D) participated in a one-hour virtual listening session with officials from the Food and Drug Administration (FDA). The session enabled those with ARG1-D and their caregivers to  share their experiences, perspectives, needs, goals with officials from across the agency.
During the session the patients and caregivers shared:
  • Difficulties obtaining a correct diagnosis
  • Symptoms and experiences related to living with ARG1-D
  • The impact or the condition on daily functioning and quality of life
  • Experiences and challenges with existing treatments and the current state of disease management
  • The need for disease awareness, improved care guidelines, and better treatment options
The full report is shared below. 
Or Download Here

Redacted FDA Listening session

SHARE

Facebook
Twitter
LinkedIn
Skip to content